Story
TechCrunch [ai] · Artificial Intelligence
← Back to your feed

“We’re not doing 30 bets a year”: Vijay Pande on betting small after running $4 billion at a16z

Vijay Pande — who left a16z's roughly $4 billion biotech practice last year to start the much smaller, AI-native VZVC — talks about why biology is finally shifting from a "discovery" science to an "engineering" one, why clinical trials are still brutally expensive, and why he thinks open, shared datasets (not walled-off ones) are what will actually let AI transform medicine.

Read at TechCrunch [ai]

Join the conversation

Discuss the story with the TraceFeed community.

No comments yet. Be the first to add a perspective.

Make it part of your feed.

Sign up or log in to continue.